<DOC>
	<DOCNO>NCT02388347</DOCNO>
	<brief_summary>To assess safety single ascend dose MEDI7836 healthy adult male subject healthy adult female subject non-childbearing potential .</brief_summary>
	<brief_title>A Study Assess Safety MEDI7836 Healthy Adults .</brief_title>
	<detailed_description>This Phase 1a , randomise , blind ( investigator subject blind treatment assignment sponsor unblinded treatment assignment ) , placebo-controlled study evaluate safety single-ascending SC dose MEDI7836 healthy adult male subject healthy adult female subject non-childbearing potential . The study conduct single site United Kingdom ( UK ) . Four dose cohort MEDI7836 placebo plan study total 32 subject ( 24 subject receive MEDI7836 , 8 subject receive placebo ) .</detailed_description>
	<criteria>1 . Vital sign , ECG , laboratory parameter within normal range screen Day 1 2 . Negative alcohol drug screen screen Day 1 3 . Able willing comply requirement protocol 4 . Females subject must surgically sterilise postmenopausal 5 . Nonsterilised male sexually active female partner childbearing potential female partner surgically sterilise bilateral tubal ligation must use condom spermicide partner screen end study followup period 1 . Concurrent enrolment another clinical study subject receive investigational product 2 . Individuals legally institutionalise 3 . Receipt market investigational biologic agent within 4 month 4 . Receipt investigational nonbiologic agent within 3 month 5 halflives prior screen , whichever longer 5 . Use medication ( prescription counter , include herbal remedy ) within 14 day 5 halflives Day 1 , 6 . Known history allergy reaction component investigational product formulation 7 . History anaphylaxis follow biologic therapy 8 . History chronic alcohol drug abuse within 12 month prior screen , 9 . Presence positive drug alcohol screen screen Day 1 . 10 . Current smoker , history smoking within 6 month screen 11 . Pregnant breastfeed woman 12 . Any active medical psychiatric condition reason , opinion investigator medical monitor , may compromise safety subject study interfere evaluation investigational product reduce subject 's ability participate study 13 . Any clinically relevant abnormal finding physical examination , ECG , vital sign , haematology , clinical chemistry urinalysis screen Day 1 , 14 . History known primary immunodeficiency disorder use immunosuppressive medication within 12 month screen 15 . History clinically significant infection require antibiotic antiviral medication 30 day prior screen , include Day 1 16 . Diagnosis helminth parasitic infection within 6 month prior screen treat , fail respond , standard care therapy 17 . History cancer , except basal cell carcinoma situ carcinoma cervix treat apparent success curative therapy ≥ 12 month prior screen malignancy treat apparent success curative therapy ≥ 5 year prior screen 18 . Positive tuberculosis ( TB ) test ( QuantiferonTB Gold ) screen TB require treatment within 12 month prior screen visit 19 . Positive hepatitis B surface antigen , hepatitis B anticore antibody , hepatitis C virus antibody serology screen . 20 . Subjects history hepatitis B vaccination without history hepatitis B allow enter study . 21 . A positive human immunodeficiency virus test screening subject take antiretroviral medication , determine medical history and/or subject 's verbal report 22 . Evidence active liver disease , include jaundice aspartate transaminase ( AST ) , alanine transaminase ( ALT ) , alkaline phosphatase great twice upper limit normal ( ULN ) 23 . Major surgery within 8 week prior screen , plan inpatient surgery hospitalisation study period 24 . Receipt live attenuate vaccine 30 day prior date screening Where participation study would result donation blood blood product excess 500 mL within 8week period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>